Papers published in Pubmed in last 12 months
(Data retrieved on Wed Nov 18 15:02:04 IST 2015 )
- WMA Resolution on Unproven Therapy and the Ebola Virus: Adopted by the 65th WMA General Assembly, Durban, South Africa, October 2014.
- Getting the most from the Ebola vaccine success.
- Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested,
- The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats.
- Ebola vaccine and corporate responsibility.
- Evaluating Ebola vaccine trials: insights from simulation.
- [August 2015: the first encouraging results of the Ebola vaccine].
- Ebola vaccine trial falls short of homerun.
- Interim results from a phase 3 Ebola vaccine study in Guinea.
- Ebola virus vaccine: benefit and risks of adenovirus-based vectors.
- Ebola vaccine yields first hopes of clinical efficacy.
- Two Ebola vaccine candidates pass phase 2, three others in phase 1.
- Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report.
- Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report.
- INFECTIOUS DISEASES. Unusual Ebola vaccine study pays off in Guinea.
- EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
- An Ebola vaccine: first results and promising opportunities.
- The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
- Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.
- How Ebola-vaccine success could reshape clinical-trial policy.
- Ebola vaccine trial results are "extremely promising," says WHO.
- The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola.
- A thermostable, chromatographically purified Ebola nano-VLP vaccine.
- Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
- Stakeholders' engagement with Ebola therapy research in resource limited settings.
- Acceptability and Willingness-to-Pay for a Hypothetical Ebola Virus Vaccine in Nigeria.
- Traditional passive immune therapy for emerging Ebola infection.
- Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola.
- Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.
- [Overview of Ebola virus vaccine].
- Approaches to demonstration of Ebola virus vaccine efficacy.
- Ebola vaccine trial in Guinea.
- Ebola vaccine trial in west Africa faces criticism.
- Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
- Long-term vaccine strategies for Ebola.
- The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases.
- A vaccine against Ebola: Problems and opportunities.
- Ebola vaccine trials: a race against the clock.
- Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis.
- Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study.
- Early trials of Ebola vaccine show immune response.
- Vaccine testing. Ebola and beyond.
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe - Preliminary Report. (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was
- A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report. than 24,000 cases and 10,000 deaths. We present a preliminary report from two
- A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose.
- An updated Ebola vaccine: immunogenic, but will it protect?
- Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
- Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.
- Safety of recombinant VSV-Ebola virus vaccine vector in pigs.
- A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact.
- Share the risks of Ebola vaccine development.
- New Ebola vaccine trial is underway.
- Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
- A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
- Is the world ready for an Ebola vaccine?
- Clinical trials of Ebola vaccine must continue despite fall in number of cases.
- Preparing for renal replacement therapy in patients with the Ebola virus disease.
- Progress of vaccine and drug development for Ebola preparedness.
- Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease.
- Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.
- Ebola vaccine is safe and immunogenic, results show.
- Antibody therapy to limit the spread of Ebola virus.
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report. 8500 deaths. A vaccine could contribute to outbreak control in the region. We
- Ebola vaccine candidates are tested in humans.
- Ebola vaccine to be tested on 30,000 volunteers.
- Ebola vaccine trials back on track.
- Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections.
- Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
- The Ebola Epidemic. High hopes for Guinean vaccine trial.
- Ebola, dogs and a vaccine.
- Trials of Ebola vaccine set to begin in west Africa.
- Loperamide therapy for voluminous diarrhea in Ebola virus disease.
- Ebola hemorrhagic Fever and the current state of vaccine development.
- Ebola raises profile of blood-based therapy.
- Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.
- A race for an Ebola vaccine: promises and obstacles.
- Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net.
- Ebola therapy and health equity.
- Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.
- International community ramps up Ebola vaccine effort.
- Positive results spur race for Ebola vaccine.
- Minimizing risks associated with renal replacement therapy in patients with Ebola virus disease.
- Is Canada patent deal obstructing Ebola vaccine development?
- Ebola therapy: Developing new drugs or repurposing old ones?
- Adrian Hill: accelerating the pace of Ebola vaccine research.
- One Step Closer to an Ebola Virus Vaccine. virus disease (EVD) in some parts of West Africa,1 the remaining pockets of
- Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report. prompted an international response to accelerate the availability of a preventive
- Using the Ebola outbreak as an opportunity to educate on vaccine utility.